1. Home
  2. CYT

CYT

Cyteir Therapeutics Inc.

Logo Cyteir Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-02-2024 9:37am EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

Founded: 2012 Country:
United States
United States
Employees: N/A City: LEXINGTON
Market Cap: 110.5M IPO Year: 2021
Target Price: $3.00 AVG Volume (30 days): 167.6K
Analyst Decision: Hold Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.94 EPS Growth: N/A
52 Week Low/High: $1.65 - $3.19 Next Earning Date: 05-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: